Related Experiment Video

Updated: Jun 5, 2025

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

9.4K

Oncolytic senecavirus A in tumor immunotherapy: Mechanisms, progress, and future directions

Xiaoya Zhao1, Wenjie Li1, Yuan Sun1

  • 1College of Animal Science, South China Agricultural University, Guangzhou, Guangdong, 510642, China.

Virology
|December 12, 2024
PubMed

Insights

Senecavirus A (SVA) is a novel oncolytic virus therapy for cancer. This picornavirus offers targeted tumor cell lysis, enhanced gene delivery, and a strong safety profile, representing a promising immunotherapy approach.

Area of Science:

  • Oncology
  • Virology
  • Immunotherapy

Background:

  • Oncolytic virotherapy is a developing cancer immunotherapy strategy.
  • Senecavirus A (SVA), a picornavirus, is the first of its kind investigated for oncolytic potential in humans.
  • SVA exhibits characteristics suitable for cancer treatment, including tumor vascular penetration and specific tumor cell targeting.

Purpose of the Study:

  • To review the mechanisms of action of Senecavirus A (SVA) in oncolytic therapy.
  • To summarize the research progress of SVA in cancer treatment.
  • To identify challenges and future directions for SVA-based oncolytic virotherapy.

Main Methods:

  • Literature review of studies on Senecavirus A (SVA) and oncolytic virotherapy.
  • Analysis of SVA's biological properties, including replication, genetic structure, and safety profile.
  • Evaluation of SVA's potential for genetic modification and therapeutic enhancement.

Main Results:

  • SVA demonstrates effective tumor cell targeting and lysis due to its size, replication rate, and vascular penetration capabilities.
  • SVA's non-integration into the host genome and lack of oncogenes contribute to a favorable safety profile, with no observed pathogenicity in humans or animals.
  • SVA's genetic structure allows for modifications to carry therapeutic genes, potentially improving treatment efficacy.

Conclusions:

  • Senecavirus A (SVA) presents a promising platform for oncolytic virotherapy due to its targeted action, safety, and genetic adaptability.
  • Further research and clinical trials are warranted to fully explore SVA's potential in cancer immunotherapy.
  • Addressing current challenges will be crucial for the successful clinical translation of SVA-based therapies.
Keywords:
ImmunotherapyOncologyOncolytic virusSenecavirus A

More Related Videos

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats08:55

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

9.5K
Ex Vivo Infection of Live Tissue with Oncolytic Viruses12:08

Ex Vivo Infection of Live Tissue with Oncolytic Viruses

Published on: June 25, 2011

12.6K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
476
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
338
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.